GU Cancers 2020 | Nivolumab for nccRCC
VJOncology is committed to improving our service to you
Thanks for your feedback, this will help us improve our content for you!
Laurence Albiges, MD, PhD, Gustave Roussy Institute, Villejuif, France discusses the methods and results of the ACSe study (NCT03012581), which investigated the use of nivolumab in rare cancers such as metastatic non-clear cell renal cell carcinoma (nccRCC). This interview took place at the 2020 Genitourinary Cancers Symposium, held in San Francisco, CA.
Get great new content delivered to your inboxSign up